Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

733.O1.8 Autologous Transplantation: Myeloma, Amyloidosis and Autoimmune Diseases

Monday, December 8, 2008: 7:00 AM-9:00 AM
120-121-122-123-124-125 - North (Moscone Center)
Moderators:
Asad Bashey, MD, PhD and Edward A. Stadtmauer, MD
7:00 AM
Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Henk Lokhorst1, Bronno van der Holt2*, Sonja Zweegman, MD, PhD3, Peter A. Von Dem Borne, MD, PhD4, Gerard M.J. Bos, MD, PhD5, Sandra Croockewit, MD, PhD6*, Jan J. Cornelissen, MD, PhD7, Marinus van Oers8*, Martyn Ronald Schaafsma9, Harm Sinnige, MD, PhD10*, Michel Delforge, MD, PhF11*, Okke de Weerdt12*, Pierre W Wijermans13, Shulamiet Wittebol, MD, PhD14*, Edo Vellenga, MD, PhD15*, Asiong Jie12*, Henriette Berenschot, MD, PhD16*, Marinus Marwijk-kooy, MD, PhD17* and Pieter Sonneveld, MD, PhD18

1Hematology, University Medical Center Utrecht, Utrecht, Netherlands
2Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
3Dept. of Hematology, 2pk BR018, VUMC, Amsterdam, Netherlands
4Stafcentrum Hematologie, C2-R, Leids University Medical Center,, Leiden, Netherlands
5Dept. of Internal Medicine, University Hospital Maastricht, Maastricht, Netherlands
6Haematology, University Medical Center St Radboud, Nijmegen, Netherlands
7Hematology, Erasmus MC/Daniel Den Hoed, Rotterdam, Netherlands
8AMC
9Medisch Spectrum Twente, Enschede, Netherlands
10Haematology 3/12, Jeroen Bosch Hospital, 's Hertogenbosch, Netherlands
11Myeloma Study Group, Belgian Hematological Socirty, Leuven, Belgium
12HOVON, Netherlands
13Hospital Leyenburg, The Hague, Netherlands
14Haematology, locatie Elisabeth, Meander Medical Center Amersfoort, Amersfoort
15Haematology, University Medical Center Groningen, Groningen, Netherlands
16Internal Medicine, Albert Schweitzer Hospital, location Dordwijk, Dordrecht, Netherlands
17Isala kliniek Zwolle
18Hematology, Erasmus Medical Center Rotterdam

7:15 AM
Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Michele Cavo, M.D.1*, Paola Tacchetti, M.D.1*, Francesca Patriarca, M.D.2*, Maria Teresa Petrucci, M.D.2*, Lucia Pantani, M.D.1*, Michela Ceccolini, M.D.1*, Monica Galli, M.D.2*, Francesco Di Raimondo, M.D.2*, Claudia Crippa, M.D.2*, Elena Zamagni, M.D.1*, Patrizia Tosi, M.D.1*, Franco Narni, M.D.2*, Sara Bringhen, M.D.2*, Vittorio Montefusco, M.D.2*, Massimo Offidani, M.D.2*, Silvia Buttignol, M.D.2*, Anna Levi, M.D.2*, Ausilia Gorgone, M.D.2*, Annamaria Brioli, M.D.1*, Maria Caterina Pallotti, M.D.1*, Tonino Spadano, M.D.2*, Norbert Pescosta, M.D.2*, Luca Baldini, M.D.2*, Antonio Ledda, M.D.2*, Tommaso Caravita, M.D.2*, Antonietta Falcone, M.D.2*, Alfonso Zaccaria, M.D.2*, Giulia Perrone, M.D.1*, Alessandro Petrucci, M.D.1*, Antonio Palumbo, M.D.2*, Mario Boccadoro, M.D.2* and Michele Baccarani, M.D.3

1Seragnoli Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy
2Italian Myeloma Network GIMEMA, Italy
3Dept. Hematology and Medical Oncology, University of Bologna, Bologna, Italy

7:30 AM
Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients

Antonio Palumbo, MD1, Patrizia Falco, MD1*, Francesca Gay, MD1*, Vittorio Montefusco, MD2*, Claudia Crippa, MD2*, Francesca Patriarca, MD2*, Milena Gilestro, PhD1*, Anna M. Liberati, MD2*, Fausto Rossini, MD2*, Tommaso Caravita, MD2*, Antonietta Falcone, MD2*, Federica Cavallo, MD1*, Paolo Corradini, MD2*, Giuseppe Rossi, MD2* and Mario Boccadoro, MD1*

1Divisione di Ematologia dell'Università di Torino, A.O.U. San Giovanni Battista, Torino, Italy
2Italian Multiple Myeloma Network, GIMEMA, Italy

7:45 AM
Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL

Murielle Roussel1*, Anne Huynh1*, Philippe Moreau2*, Jean Luc Harousseau2*, Cyrille Hulin3*, Denis Caillot4*, Christophe Fruchart5*, Gerald Marit6*, Brigitte Pegourie7* and Michel Attal1

1IFM, CHU Purpan, Toulouse, France
2IFM, CHU Hotel Dieu, Nantes, France
3IFM, CHU Brabois, Vandoeuvre, France
4IFM, CHU Bocage, Dijon, France
5IFM, Centre Baclesse, Caen, France
6IFM, CHU Bordeaux, Pessac, France
7IFM, CHU Michallon, Grenoble, France

8:00 AM
Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective StudyClinically Relevant Abstract

Juan José Lahuerta1*, Maria Victoria Mateos2*, Joaquin Martínez-López1*, Laura Rosinol3*, Anna Sureda4*, Javier de la Rubia5*, José García-Laraña6*, Rafael Martínez-Martínez7*, Miguel-Teodoro Hernández-García8*, Dolores Carrera9*, Juan Besalduch, MD, PhD10, Felipe de Arriba11*, Jose-Maria Ribera12*, Lourdes Escoda13*, María-Belen Hernández-Ruiz14*, Javier García-Frade15*, Concepción Rivas-González16*, Adrian Alegre17, Joan Blade18 and J.F. San Miguel19

1Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
2Haematology, Hospital Universitario de Salamanca, Salamanca
3Hematology, Hospital Clinic i Provincial, Barcelona, Spain
4Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
5Hospital La Fe, Valencia, Spain
6PETHEMA/Spanish Myeloma Group
7Hematology, Hospital Clínico, Madrid, Spain
8Hematology, Hospital Universitario de Canarias, Tenerife, Spain
9Hospital Central de Asturias, Oviedo, Spain
10Hematology, Complejo Asistencial Son Dureta, Bendinat, Spain
11Hematology, Hospital Morales Messeguer, Murcia, Spain
12Hospital Germans Trials i Pujol, Badalona, Spain
13Hematology, Hospital Joan XXIII, Tarragona, Spain
14Hematology, Hospital Nuestra Señora de Alarcos, Ciudad Real, Spain
15Hematology, Hospital Rio Hortega, Valladolid, Spain
16Hematology, Hospital General de Alicante, Alicante, Spain
17Hematology, Hosp. Universitario del la Princesa, Madrid, Spain
18Hospital Clinic, IDIBAPS, Barcelona, Spain
19HematologÃa, IBMCC, Centro de Investigación del Cðncer, Universidad de Salamanca-CSIC; Hospital ClÃnico Universitario, Salamanca, Spain

8:15 AM
Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5Clinically Relevant Abstract

Bart Barlogie, MD, PhD1, Elias J. Anaissie, MD1, John D. Shaughnessy Jr., PhD1, Frits van Rhee, MD, PhD1*, Mauricio Pineda-Roman, MD1*, Jeff Haessler, MD2*, Klaus A. Hollmig, MD1*, Yazan Alsayed, MD1*, Sarah Waheed, MD1*, Monica Graziutti, MD1*, Elias Kiwan, MD1* and John Crowley, PhD2

1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
2Cancer Research & Biostatistics, Seattle, WA

8:30 AM
High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON)

Bouke P.C. Hazenberg, MD, PhD1*, Sandra Croockewit, MD, PhD2*, Ron van der Holt, MD, PhD3*, Sonja Zweegman, MD, PhD4, Gerard Bos, MD, PhD5*, Peter Vandenberghe, MD, PhD6, Pieter Sonneveld, MD, PhD7, Jan J. Cornelissen, MD, PhD8, Edo Vellenga, MD, PhD9, Pierre W. Wijermans, MD, PhD10, Roelof Willemze, MD, PhD11, Marinus H.J. Van Oers, MD, PhD12, Okke de Weerdt13*, Fokje M. Spoelstra, PhD3* and Henk Lokhorst, MD, PhD14

1Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
2Haematology, University Medical Center St Radboud, Nijmegen, Netherlands
3HOVON Data Center, Netherlands
4Dept. of Hematology, 2pk BR018, VUMC, Amsterdam, Netherlands
5Dept. of Hematology, Academic Hospital Maastricht, Maastricht, Netherlands
6Human Genetics, KULeuven, Leuven, Belgium
7Hematology, Erasmus Medical Center Rotterdam
8Hematology, Erasmus MC/Daniel Den Hoed, Rotterdam, Netherlands
9Hematology, University Medical Hospital Groningen, Groningen, Netherlands
10Hospital Leyenburg, The Hague, Netherlands
11Dept. of Hematology, Leiden Univ. Med. Ctr., Leiden, Netherlands
12Hematology, Academic Medical Center Amsterdam, Amsterdam, Netherlands
13HOVON, Netherlands
14Hematology, University Medical Center Utrecht, Utrecht, Netherlands

8:45 AM
Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases:  10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases

Dominique Farge1*, Myriam Labopin2*, Alan Tyndall3*, Athanasios Fassas4*, Gian Luigi Mancardi5*, Jaap Van Laar6*, Jian Ouyang7*, Tomas Kozak8*, John Moore9, Ina Kötter10*, Virginie Chesnel11*, Alberto Marmont12*, Alois Gratwohl, MD13* and Riccardo Saccardi14*

1Internal medicine and vascular pathology, Saint Louis Hospital, Paris, France
2Hopital Saint-Antoine, Université Pierre et Marie Curie Paris 6, Paris 75571, France
3Rheumatologische Uniklinik, Felix Platter Spital, Basel, Switzerland
4Hematology-BMT unit, George Papanicolaou Hospital, Thessaloniki, Greece
5Clinica Neurologica Università, Ospedale San Martino, Genova, Italy
6Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne, United Kingdom
7Department of Haematology, Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
8Department Of Clinical Hematology,, University Hospital Kralovske Vinohrady, Prague, Czech Republic
9Haematology Department, St. Vincents Hospital, Sydney, Australia
10Medizinische Klinik 2, Tübingen, Germany
11Hopital Saint-Antoine, Université Pierre et Marie Curie Paris 6, Paris, France
12Department of Haematology II, Ospedale San Martino, Genova, Italy
13Hematology, University Hospital of Basel, Basel, Switzerland
14BMT Unit, Department of Hematology, Policlinico di Careggi, Firenze, Italy

*signifies non-member of ASH